Population Models for Drug Absorption and Enterohepatic Recycling

Pharmacometrics: The Science of Quantitative Pharmacology

Volumn , Issue , 2006, Pages 345-382

  Pétricoul, Olivier ^a   Cosson, Valérie ^b,c   Fuseau, Eliane ^a   Marchand, Mathilde ^a  

^a EMF Consulting   (France)

^b GSK   (Italy)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Absorption; Amount absorbed; Asymmetric S shape absorption profiles; Atypical absorption models; Atypical absorption models saturable time constraint absorption model with a storage compartment; Dual site absorption models; Entero hepatic recycling; Erlang frequency distribution; First order absorption model; Individual analysis; Inverse Gaussian input, and gamma distribution; Mixture of first order and zero order absorption model; NONMEM; Pharmacodynamics; Pharmacokinetics; Physico chemical properties of a compound; Population modeling; Rate and extent of drug absorption; Rate of absorption; Secondary peaks; Transit model for saturable small intestinal absorption; Two parallel first order absorptions model; Weibull type absorption model; Zero order absorption model

Indexed keywords

EID: 67649947275     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470087978.ch13     Document Type: Chapter

References (92)

1. R. A. Prentis, Y. Lis, and S. R. Walker, Pharmaceutical innovation by the seven UKowned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 25:387-396 (1988).
2. R. T. Borchardt, P. L. Smith, and G. Wilson, General principles in the characterization and use of model systems for biopharmaceuticals studies. Pharm Biotechnol 8:1-11 (1996).
3. L. J. Lesko, M. Rowland, C. C. Peck, and T. F. Blaschke, Optimizing the science of drug development: opportunities for better candidates selection and accelerated evaluation in humans. J Clin Pharmacol 40:803-814 (2000).
4. C. C. Peck, W. H. Barr, L. Z. Benet, J. Collins, R. E. Desjardins, D. E. Furst, J. G. Harter, G. Levy, T. Ludden, and J. H. Rodman, Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in drug development. J Clin Pharmacol 34:111-119 (1994).
5. C. A. Lipinsky, Drug-like properties and the cause of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44:235-249 (2000).
6. B. J. Aungst, Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci 82:979-987 (1993).
7. H. Zhou, Pharmacokinetic strategies in deciphering atypical drug absorption profiles. J Clin Pharmacol 43:211-227 (2003).
8. H. Zhou, Analysis of absorption kinetic data, in Pharmacokinetics in Drug Development: Clinical Study Design and Analysis, Vol. 1, P. L. Bonate and D. R. Howard (Eds.). AAPS Press, New York, 2004, pp. 383-422.
9. W. L. Chiou, The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarification and recommendation of terminology. J Pharmacokinet Pharmacodyn 28:3-6 (2001).
10. C. Duquesnoy, L. F. Lacey, O. N. Keene, and A. Bye, Evaluation of different partial AUCs as indirect measures of rate of drug absorption in comparative pharmacokinetic studies. Eur J Pharm Sci 6:259-264 (1998).
11. D. Fleisher, C. Li, Y. Zhou, L. H. Pao, and A. Karim, Drug, meal and formulation interactions influencing drug absorption after oral administration clinical implications. Clin Pharmacokinet 36:233-254 (1999).
12. C. H. Kleinbloesem, P. Van Brummelen, M. Danhof, et al., Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamics effect in humans. Clin Pharm Ther 41:26-30 (1987).
13. E. H. Cox, C. Veyrat-Follet, S. L. Beal, E. Fuseau, S. Kenkare, and L. B. Sheiner, A population pharmacokinetic-pharmacodynamic analysis of repeated measures time-toevent pharmacodynamic responses: the antiemetic effect of ondansetron. J Pharmacokinet Biopharm 27:625-644 (1999).
14. S. L. Collins, C. C. Faura, R. A. Moore, and H. J. McQuay, Peak plasma concentration after oral morphine: systemic review. J Pain Symtom Manage 16:388-402 (1998).
15. E. Fuseau, O. Petricoul, A. Sabin, A. Pereira, S. O'Quinn, S. Thein, M. Leibowitz, H. Purdon, S. McNeal, R. Salonen, A. Metz, and P. Coates, Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine. Clin Ther 23:242-251 (2001).
16. D. A. Sica, Pharmacotherapy in congestive heart failure: drug absorption in the management of congestive heart failure: loop diuretics. Congestive Heart Failure 9:287-292 (2003).
17. L. K. M. De Bruyne, Mechanisms and management of diuretic resistance in congestive heart failure. Postgrad Med J 79:268-271 (2003).
18. E. Rubinstein and J. Camm, Cardiotoxicity of fluoroquinolones. J Antimicrob Chemother 49:593-596 (2002).
19. J. L. Demolis, D. Kubitza, L. Tenneze, and C. Funck-Brentano, Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects. Clin Pharmacol Ther 68:658-666 (2000).
20. S. Barriere, F. Genter, E. Spencer, M. Kitt, D. Hoelscher, and J. Morganroth, Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 44:689-695 (2004).
21. C. MacDougall and B. J. Guglielmo, Pharmacokinetics of valaciclovir. J Antimicrob Chemother 53:899-901 (2004).
22. A. Schwarz and A. Perez-Canto, Nephrotoxicity of antiinfective drugs. Int J Clin Pharmacol Ther 36:164-167 (1998).
23. H. Echizen and M. Eichelbaum, Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 11:425-449 (1986).
24. V. Luckow and O. Della Paschoa, PKPD modeling of high-dose ditliazem-absporptionrate dependency of the hysteresis loop. Int J Clin Pharmacol Ther 35:418-425 (1997).
25. M. D. Cheitlin, A. M. Hutter, R. G. Brindis, P. Ganz, S. Kaul, R. O. Russell, and R. M. Zusman, Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 99:168-177 (1999).
26. D. J. Nichols, G. J. Muirhead, and J. A. Harness, Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Clin Pharmacol 53(Suppl 1):5S-12S (2002).
27. M. F. Delgado Iribarnegaray, D. Santo Bueldga, M. J. Garcia Sanchez, M. J. Otero, A. C. Falcao, and A. Dominguez-Gil, Carbamazepine population pharmacokinetics in children: mixed-effect models. Ther Drug Monit 19:132-139 (1997).
28. D. S. Stein, Y. Lou, M. Johnson, S. Randall, and S. Blanche, Pharmacokinetic and pharmacodynamic analysis of amprenavir-containing combination therapy in HIV-1-infected children. J Clin Pharmacol 44:1301-1308 (2004).
29. D. Hickman, S. Vasavanonda, G. Nequist, L. Colletti, W. M. Kati, R. Bertz, A. Hsu, and D. J. Kempf, Estimation of serum-free 50-percent inhibitory concentrations for human immunodeficiency virus protease inhibitors lopinavir and ritonavir. Antimicrob Agents Chemother 48:2911-2917 (2004).
30. E. Iisalo, Clinical pharmacokinetics of digoxin. Clin Pharmacokinet 2:1-16 (1977).
31. M. Weiss and W. Kang, Inotropic effect of digoxin in humans: mechanistics pharmacokinetic/pharmacodynamic model based on slow receptor binding. Pharm Res 21:231-236 (2004).
32. G. E. Granero, C. Ramachanda, and G. L. Amidon, in Drug Bioavailability. Estimation of Solubility, Permeability, Absorption, and Bioavailability, Vol. 18, H. Van de Waterbeemd, H. Lennernäs, and P. Artursson (Eds.). Wiley-VCH, Hoboken, NJ, 2004, pp. 191-214.
33. H. Van de Waterbeemd, H. Lennernäs, and P. Artursson (Eds.), Drug Bioavailability. Estimation of Solubility, Permeability, Absorption, and Bioavailability, Vol. 18. Wiley-VCH, Hoboken, NJ, 2004, pp. 3-20.
34. M. N. Martinez and G. L. Amidon, A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol 42:620-643 (2002).
35. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison, Theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420 (1995).
36. K. C. Johnson and A. C. Swindell, Guidance in the setting of drug particle size specifications to minimize variability in absorption. Pharm Res 13:1795-1798 (1996).
37. B. Agoram, W. S. Woltosz, and M. B. Bolger, Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50(Suppl 1):S41-S67 (2001).
38. P. Stenberg, C. A. Bergstrom, K. Luthman, and P. Artursson, Theoretical predictions of drug absorption in drug discovery and development. Clin Pharmacokinet 41:877-899 (2002).
39. N. M. Idkaidek, G. L. Amidon, D. E. Smith, N. M. Najib, and M. M. Hassan, Determination of the population pharmacokinetic parameters of sustained-release and entericcoated oral formulations, and the suppository formulation of diclofenac sodium by simultaneous data fitting using NONMEM. Biopharm Drug Dispos 19:169-174 (1998).
40. C. Csajka, T. Buclin, K. Fattinger, H. R. Brunner, and J. Biollaz, Population pharmacokinetic- pharmacodynamic modeling of angiotensin receptor blockade in healthy volunteers. Clin Pharmacokinet 41:137-152 (2002).
41. Y. M. Wang and R. H. Reuning, An experimental design strategy for quantitating complex pharmacokinetic models: enterohepatic circulation with time-varying gallbladder emptying as an example. Pharm Res 9:169-177 (1992).
42. Y. Plusquellec, G. Campiston, S. Staveris, J. Barre, L. Jung, J. P. Tillement, and G. Houin, A double-peak phenomenon in the pharmacokinetics of veralipride after oral administration: a double-site model for drug absorption. J Pharmacokinet Biopharm 15:225-239 (1987).
43. A. M. Holgate and N. M. Read, Effect of ileal infusion of intralipid on gastrointestinal transit, ileal flow rate, and carbohydrate absorption in humans after ingestion of a liquid meal. Gastroenterology 88:1005-1011 (1985).
44. R. L. Oberle and G. L. Amidon, The influence of variable gastric emptying and intestinal rates on the plasma level curve of cimetidine: an explanation for the double peak phenomenon. J Pharmacokinet Biopharm 15:529-544 (1987).
45. P. H. Marathe, E. P. Sandefer, G. E. Kollia, D. S. Greene, R. H. Barbhaiya, R. A. Lipper, R. C. Page, W. Doll, U. Y. Ryo, and G. A. Digenis, In vivo evaluation of the absorption and gastrointestinal transit of avitriptan in fed and fasted subjects using gamma scintigraphy. J Pharmacokinet Biopharm 26:1-20 (1998).
46. E. Lipka, I. D. Lee, P. Langguth, H. Spahn-Langguth, E. Mutschler, and G. L. Amidon, Celiprolol double-peak and gastric motility: non-linear mixed effect modeling of bioavailability data obtained in dogs. J Pharmacokinet Biopharm 23:267-287 (1995).
47. W. N. Charman, M. Rogge, A. W. Body, W. H. Barr, and B. M. Berger, Absorption of danazol after administration to different sites of the gastrointestinal tract and the relationship to single- and double-peak phenomena in the plasma profiles. J Clin Pharmacol 33:1207-1213 (1993).
48. Y. Wang, A. Roy, L. Sun, and C. E. Lau, A double-peak phenomenon in the pharmacokinetics of alprazolam after oral administration. Drug Metab Dispos 27:855-859 (1999).
49. P. Veng Pedersen, Pharmacokinetic analysis by linear system approach I: cimetidine bioavailability and second peak phenomenon. J Pharm Sci 70:32-38 (1981).
50. I. F. Troconiz, S. Armenteros, M. V. Planelles, J. Benitez, R. Calvo, and R. Dominguez, Pharmacokinetic-pharmacodynamic modeling of the antipyretic effect of two oral formulations of ibuprofen. Clin Pharmacokinet 38:505-518 (2000).
51. K. Murata, K. Noda, K. Kohno, and M. Samejima, Pharmacokinetic analysis of concentration data of drugs with irregular absorption profiles using multi-fraction absorption models. J Pharm Sci 76:109-113 (1987).
52. K. Murata, H. Yamahara, M. Kobayashi, K. Noda, and M. Samejima, Pharmacokinetics of an oral sustained-release diltiazem preparation. J Pharm Sci 78:960-963 (1989).
53. I. Mahmood, Pharmacokinetic analysis of the absorption characteristics of diclofenac sodium in man by use of a multi-segment absorption model. J Pharm Pharmacol 48:1260-1263 (1996).
54. T. Funaki, N. Watari, S. Furata, and N. Kaneniwa, Analysis of the absorption characteristics of cimetidine with the use of the multi-segment absorption model. Int J Pharm 43:59-65 (1988).
55. K. Murata and K. Noda, Pharmacokinetic analysis of an oral sustained-release diltiazem preparation using multifraction absorption models. Pharm Res 10:757-762 (1993).
56. V. F. Cosson and E. Fuseau, Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients. J Pharmacokinet Biopharm 27:149-171 (1999).
57. F. Bouzom, C. Laveille, H. Merdjan, and R. Jochemsen, Use of nonlinear mixed effect modeling for the meta-analysis of preclinical pharmacokinetic data: application to S 20342 in the rat. J Pharm Sci 89:603-613 (2000).
58. T. M. Garrigues, U. Martin, J. E. Peris-Ribera, and L. F. Prescott, Dose-dependent absorption and elimination of cefadroxil in man. Eur J Clin Pharmacol 41:179-183 (1991).
59. N. H. Holford, R. J. Ambros, and K. Stoeckel, Models for describing absorption rate and estimating extent of bioavailability: application to cefetamet pivoxil. J Pharmacokinet Biopharm 20:421-442 (1992).
60. S. Rietbrock, P. G. Merz, U. Fuhr, S. Harder, J. P. Marschner, D. Loew, and J. Biehl, Absorption behavior of sulpiride described using Weibull functions. Int J Clin Pharmacol Ther 33:299-303 (1995).
61. D. Hartmann, D. Gysel, U. C. Dubach, and I. Forgo, Pharmacokinetic modeling of the plasma concentration-time profile of the vitamin retinyl palmitate following intramuscular administration. Biopharm Drug Dispos 11:689-700 (1990).
62. D. Smith, R. Enever, M. Dey, D. Latta, and R. Weierstall, Pharmacokinetics and bioavailability of medroxyprogesterone acetate in the dog and the rat. Biopharm Drug Dispos 14:341-355 (1993).
63. F. Bressolle, R. Gomeni, R. Alric, M. J. Royer-Morrot, and J. Necciari, A double Weibull input function describes the complex absorption of sustained-release oral sodium valproate. J Pharm Sci 83:1461-1464 (1994).
64. S. Appel-Dingemanse, M. O. Lemarechal, A. Kumle, M. Hubert, and E. Legangneux, Integrated modeling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration. Br J Clin Pharmacol 47:483-491 (1999).
65. H. Zhou, S. Khalilieh, H. Lau, M. Guerret, S. Osborne, L. Alladina, A. L. Laurent, and J. F. McLeod, Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919). J Clin Pharmacol 39:911-919 (1999).
66. C. Padoin, M. Tod, N. Brion, K. Louchahi, V. Le Gros, and O. Petitjean, Pharmacokinetics of amoxicillin coadministered with a saline-polyethylene glycol solution in healthy volunteers. Biopharm Drug Dispos 16:169-176 (1995).
67. V. K. Piotrovskij, G. Paintaud, G. Alvan, and T. Trnovec, Modeling of the saturable time-constrained amoxicillin absorption in humans. Pharm Res 11:1346-1351 (1994).
68. L. X. Yu and G. L. Amidon, Saturable small intestinal drug absorption in humans: modeling and interpretation of cefatrizine data. Eur J Pharm Biopharm 45:199-203 (1998).
69. A. Rousseau, F. Leger, Y. Le Meur, F. Saint-Marcoux, G. Paintaud, M. Buchler, and P. Marquet, Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator. Ther Drug Monit 26:23-30 (2004).
70. M. Weiss, A novel extravascular input function for the assessment of drug absorption in bioavailability studies. Pharm Res 13:1457-1553 (1996).
71. X. Zhang, K. Nieforth, J. M. Lang, R. Rouzier-Panis, J. Reynes, A. Dorr, S. Kolis, M. R. Stiles, T. Kinchelow, and I. H. Patel, Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 72:10-19 (2002).
72. J. Debord, E. Risco, M. Harel, Y. Le Meur, M. Buchler, G. Lachatre, C. Le Guellec, and P. Marquet, Application of a gamma model of absorption to oral cyclosporin. Clin Pharmacokinet 40:375-382 (2001).
73. M. S. Roberts, B. M. Magnusson, F. J. Burczynski, and M. Weiss, Enterohepatic circulation: physiological, pharmacokinetic and clinical implications. Clin Pharmacokinet 41:751-790 (2002).
74. T. B. Vree and A. J. Van der Ven, Clinical consequences of the biphasic elimination kinetics for the diuretic effect of furosemide and its acyl glucuronide in humans. J Pharm Pharmacol 51:239-248 (1999).
75. R. E. Bullingham, A. J. Nicholls, and B. R. Kamm, Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34:429-455 (1998).
76. K. Elomaa, S. Ranta, J. Tuominen, and P. Lahteenmaki, The possible role of enterohepatic cycling on bioavailability of norethisterone and gestodene in women using combined oral contraceptives. Contraception 63:13-18 (2001).
77. Y. J. Sue and M. Shannon, Pharmacokinetics of drugs in overdose. Clin Pharmacokinet 23:93-105 (1992).
78. D. J. Back and M. L. Orme, Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet 18:472-484 (1990).
79. W. A. Colburn, F. M. Vane, C. J. Bugge, D. E. Carter, R. Bressler, and C. W. Ehmann, Pharmacokinetics of 14C-isotretinoin in healthy volunteers and volunteers with biliary T-tube drainage. Drug Metab Dispos 13:327-332 (1985).
80. A. Hellstern, D. Hellenbrecht, R. Saller, M. Gatzen, G. Achtert, P. Brockmann, and H. J. Hausleiter, Minimal biliary excretion and enterohepatic recirculation of metoclopramide in patients with extrahepatic cholestasis. Eur J Clin Pharmacol 45:415-418 (1993).
81. R. Lenzen, A. Bahr, H. Eichstadt, U. Marshall, W. O. Bechstein, and P. Neuhaus, In liver transplantation T tube bile represents total bile flow: physiological, and scintigraphic studies on biliary secretion of organic anions. Liver Transpl Surg 5:8-15 (1999).
82. J. E. Peris-Ribera, F. Torres-Molina, M. C. Garcia-Carbonell, J. C. Aristorena, and L. Granero, General treatment of the enterohepatic recirculation of drugs and its influence on the area under the plasma level curves, bioavailability, and clearance. Pharm Res 9: 1306-1313 (1992).
83. R. L. Semmes and D. D. Shen, A reversible clearance model for the enterohepatic circulation of drug and conjugate metabolite pair. Drug Metab Dispos 18:80-87 (1990).
84. T. Wajima, Y. Yano, and T. Oguma, A pharmacokinetic model for analysis of drug disposition profiles undergoing enterohepatic circulation. J Pharm Pharmacol 54:929-934 (2002).
85. T. Funaki, Enterohepatic circulation model for population pharmacokinetic analysis. J Pharm Pharmacol 51:1143-1148 (1999).
86. B. Ploeger, T. Mensinga, A. Sips, J. Meulenbelt, and J. De Jongh, A human physiologicallybased model for glycyrrhzic acid, a compound subject to presystemic metabolism and enterohepatic cycling. Pharm Res 17:1516-1525 (2000).
87. K. Strandgarden, P. Hoglund, L. Gronquist, L. Svensson, and P. O. Gunnarsson, Absorption and disposition including enterohepatic circulation of (14C) roquinimex after oral administration to healthy volunteers. Biopharm Drug Dispos 21:53-67 (2000).
88. Y. Plusquellec, R. Arnaud, S. Saivin, T. A. Shepard, I. Carrie, P. Hermann, J. Souhait, and G. Houin, Enterohepatic recirculation of the new antihypertensive drug UP 269-6 in humans. A possible model to account for multiple plasma peaks. Arzneimittelforschung 48:138-144 (1998).
89. F. Ezzet, G. Krishna, D. B. Wexler, P. Statkevich, T. Kosoglou, and V. K. Batra, A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibe. Clin Ther 23:871-885 (2001).
90. N. H. Holford, H. C. Kimko, J. P. Monteleone, and C. C. Peck, Simulation of clinical trials. Annu Rev Pharmacol Toxicol 40:209-234 (2000).
91. K. F. Rooney, E. Snoeck, and P. H. Watson, Modeling and simulation in clinical drug development. Drug Discov Today 6:802-806 (2001).
92. M. Sale, Modeling and simulation in drug development, promise and reality. Drug Discov World 2:47-50 (2001).